Texas Children’s Hospital to Pay $10M as Part of Detransition Settlement

Why It Matters

The settlement marks a significant escalation in state‑level regulation of pediatric gender‑affirming care, potentially setting a precedent that could reshape provider practices nationwide.

Key Takeaways

• $10 million settlement forces Texas Children’s to fund a detransition clinic
• Hospital must create a Potential GAC List and delete related press releases
• Three current and two former doctors lose medical privileges permanently
• Clinic must offer endocrinology, surgery, fertility counseling, psychiatry, OB‑GYN services
• Settlement follows Texas Bill 14 banning puberty blockers for minors

Pulse Analysis

The Texas Attorney General’s office has reached a $10 million settlement with Texas Children’s Hospital, the nation’s largest pediatric health system, that obligates the hospital to open a dedicated detransition clinic and maintain a “Potential Gender‑Affirming‑Care Patient List.” The agreement, still pending a final signature, gives the hospital 90 days from an effective date to launch multidisciplinary services—including endocrinology, surgery, fertility counseling, psychiatry and OB‑GYN—while permanently revoking the privileges of five physicians. The settlement is a direct outgrowth of Senate Bill 14, which bans puberty blockers and hormone therapy for minors.

The deal signals a new legal frontier for health providers that offer gender‑affirming care. By mandating a separate clinic for patients who wish to reverse or discontinue transition, the state is effectively institutionalizing a bifurcated model of care that could increase administrative burdens and expose hospitals to heightened scrutiny under HIPAA and state privacy statutes. Texas Children’s argues the services already exist, yet the requirement to publicize a donor page and retain a coded patient list raises questions about data security and patient confidentiality across the industry.

Nationally, the settlement may serve as a template for other states seeking to regulate or restrict transgender health services. A recent Harvard T.H. Chan School of Public Health study found fewer than one percent of minors receive puberty blockers, suggesting the market impact may be limited, but the political and financial stakes are significant. Health systems must now weigh the cost of compliance against potential reputational damage, while advocacy groups warn that such measures could deter families from seeking necessary medical care. The outcome will likely shape the future of pediatric transgender medicine in the United States.